China's rehabilitation needs for neurological disorders increased significantly from 1990 to 2021.
This cross-sectional analysis evaluated rehabilitation needs for ten neurological disorders in China from 1990 to 2021, comparing demographic aging and improved survival against global trends. The study assessed age-standardized prevalence and years lived with disability (YLDs) as primary outcomes, alongside estimated annual percentage changes (EAPCs) and forecasts to 2050 as secondary outcomes. No specific medications were analyzed, and the population encompassed the Chinese demographic experiencing aging and improved survival rates.
Results indicated that age-standardized prevalence increased significantly from 1990 to 2021, with an EAPC of 0.42 (95% CI 0.38 to 0.45). Concurrently, YLDs rates increased significantly over the same period, with an EAPC of 0.40 (95% CI 0.36 to 0.43). Among specific conditions, Parkinson's disease demonstrated the steepest proportional rise (EAPC = 1.85; 95% CI 1.78 to 1.92), followed by multiple sclerosis (EAPC = 1.42; 95% CI 1.36 to 1.48) and motor neuron disease (EAPC = 1.11; 95% CI 1.05 to 1.17). These increases exceeded global averages.
Safety and tolerability data were not reported, as the study focused on epidemiological trends rather than pharmacological interventions. A key limitation is the presence of substantial geographic and service-access inequities reported in prior national surveys, which may affect the generalizability of findings across all regions. The study does not establish causality between demographic shifts and these specific prevalence rates.
Practice relevance suggests that healthcare systems should consider decentralizing rehabilitation services and integrating disease-specific pathways into universal health coverage. Prioritizing underserved rural and older populations is essential to address the rising burden of neurological disability observed in this analysis.